1. M.D. – New Business and Partnerships
Peter Grant
M.D. – New Business and Partnerships
IP Group plc
© IP Group PLC 2018

2. The Basis for our Business
© IP Group PLC 2018
The Basis for our Business
Our operation and partners
Today
Evolving GREAT IDEAS into WORLD-CHANGING businesses

3. We are in a golden era of scientific discovery
Context - then and now?
We are in a golden era of scientific discovery
But traditional model struggled to address ‘chasm’ between science and Investors
Leading universities have a great track-record of fundamental innovation

4. The Opportunity
Research
IP Group seeks to address the chasm between research and commercial reality
Value Creation

5. Key differences to traditional Venture1 2 3
People
Partnership
Plc
Based on long-term partnerships with leading universities and providers of patient capital
Business building
Part of the Management team
No artificial 10-year life for capital invested in spin-outs
Plc levels of transparency well matched with the values of leading universities

9. Support mature UK position Continue to scale US business
Pursue emerging opportunities
(Australasia)

10. Partnership – We Succeed or Fail Together
Partnership Agreements
Close collaboration
Agreed way to work together
On site presence
Our expertise and experience
Access to pre-seed funding to develop ideas
Interest free unsecured loan
Convert on success
Convert to ordinary shares
No investment fees
No monitoring fees
Access to support services

11. Corporate activity Partnership activity IP Group’s history 2018 2000
Acquisition of Touchstone Innovations
2017
Main market & name change
2006
Flotation
2003
Launch of NE Tech Fund
2010
IP Venture Fund II
2013
Acquisition of Parkwalk Advisors
2017
Incorporated as IP2IPO
2000
Acquires Techtran & TTV
2005
Acquisition of stake in Technikos
2011
Agreement with Fusion IP
2009
Acquisition of Fusion IP
2014
Launch of IP Venture Fund
2006
2000
2018
Cardiff and Sheffield
2009
Manchester University and Cambridge Innovation Capital
2013
OSI plc
2015
Nine partners in AUS/NZ
2017
10 university partners in the UK
Oxford IBME
2011
‘Golden Triangle’
2017
Seminal deal with Oxford Chemistry
US university pilots
2013/4
Partnership activity

12. An enlarged global business
Indicative combined business
(Non-market data as at 30 June 2017)
(Non-market data as at 31 July 2017)
Partners
16 UK2
5 US3
9 Australasia
2+ UK 32
Employees 90 70
160
Market Cap1
£978m
£477m
£1,455m
Gross cash and deposits
£263m
£130m
£393m
Historic hard NAV4
£891m
£504m
£1,395m
# portfolio companies
965
48+6
1445,6
Portfolio value
£663m7
£461m7
£1,124m
Note: 1) Source: Factset, as at 06 Oct 2017; 2) Includes Oxford and Cambridge partnerships through strategic holdings in Oxford Sciences Innovation and Cambridge Innovation Capital; 3) Excludes relationships with DOE Labs through FedImpact; 4) Representative based on historic audited portfolio values as at 30 June 2017 for IP Group and 31 July 2017 for Touchstone. Touchstone balance sheet at 17 October 2017 subject to audit.; 5) Excludes holdings in three multi-sector platforms and 18 de minimis holdings; 6) Excludes 69 organic growth and lighter touch companies; and 7) Net portfolio value as reported

14. Various family offices
Investment partners
UK/ US
China
Venture
Industrial
Various family offices
Singapore
Australia

15. Broad network of aligned co-investors Patient approach
Scientific, commercial & investment expertise
Long-term university partnerships
Institutions
Family offices
Funds
Long-term capital
Access to the World class research

16. Today Total portfolio by fair value:
Total portfolio by number of companies: 3
£343.8m 74 81
£62.8m
£720.3m
Life Sciences
Technology
Multi-sector

17. Thank you for your attention
© IP Group PLC 2018